Glial cells as therapeutic targets in progressive multiple sclerosis

Brandon Wilbanks, L James Maher III, Moses Rodriguez

Research output: Contribution to journalArticle

Abstract

Introduction: Multiple sclerosis is a serious demyelinating disease of the central nervous system (CNS) with treatments generally restricted to immunosuppression to reduce attack rate and for symptom management. Glial cells may be useful targets for future CNS regenerative therapies to reverse disease. Areas covered: In this review, the authors cover currently available multiple sclerosis treatments and examine potential upcoming therapies targeting glial cells. The potential for new therapeutic approaches in the treatment of progressive multiple sclerosis is examined. Expert opinion: Microglia, astrocytes, and oligodendrocytes are each promising targets for the disease-altering treatment of multiple sclerosis. Though challenging, the opportunities presented have great potential for CNS regeneration and further investigation of glial cells in therapy is warranted. Patient-specific combinatorial therapy targeting the three glial cell types is expected to be the future of MS treatment.

Original languageEnglish (US)
Pages (from-to)481-494
Number of pages14
JournalExpert review of neurotherapeutics
Volume19
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Neuroglia
Multiple Sclerosis
Therapeutics
Central Nervous System
Oligodendroglia
Expert Testimony
Microglia
Demyelinating Diseases
Cell- and Tissue-Based Therapy
Astrocytes
Immunosuppression
Regeneration

Keywords

  • Astrocyte
  • CNS
  • glial cells
  • microglia
  • multiple sclerosis
  • oligodendrocyte
  • remyelination

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Glial cells as therapeutic targets in progressive multiple sclerosis. / Wilbanks, Brandon; Maher III, L James; Rodriguez, Moses.

In: Expert review of neurotherapeutics, Vol. 19, No. 6, 01.06.2019, p. 481-494.

Research output: Contribution to journalArticle

Wilbanks, Brandon ; Maher III, L James ; Rodriguez, Moses. / Glial cells as therapeutic targets in progressive multiple sclerosis. In: Expert review of neurotherapeutics. 2019 ; Vol. 19, No. 6. pp. 481-494.
@article{9fd6da67fa3d4e9c89d0f19e882af385,
title = "Glial cells as therapeutic targets in progressive multiple sclerosis",
abstract = "Introduction: Multiple sclerosis is a serious demyelinating disease of the central nervous system (CNS) with treatments generally restricted to immunosuppression to reduce attack rate and for symptom management. Glial cells may be useful targets for future CNS regenerative therapies to reverse disease. Areas covered: In this review, the authors cover currently available multiple sclerosis treatments and examine potential upcoming therapies targeting glial cells. The potential for new therapeutic approaches in the treatment of progressive multiple sclerosis is examined. Expert opinion: Microglia, astrocytes, and oligodendrocytes are each promising targets for the disease-altering treatment of multiple sclerosis. Though challenging, the opportunities presented have great potential for CNS regeneration and further investigation of glial cells in therapy is warranted. Patient-specific combinatorial therapy targeting the three glial cell types is expected to be the future of MS treatment.",
keywords = "Astrocyte, CNS, glial cells, microglia, multiple sclerosis, oligodendrocyte, remyelination",
author = "Brandon Wilbanks and {Maher III}, {L James} and Moses Rodriguez",
year = "2019",
month = "6",
day = "1",
doi = "10.1080/14737175.2019.1614443",
language = "English (US)",
volume = "19",
pages = "481--494",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Glial cells as therapeutic targets in progressive multiple sclerosis

AU - Wilbanks, Brandon

AU - Maher III, L James

AU - Rodriguez, Moses

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Introduction: Multiple sclerosis is a serious demyelinating disease of the central nervous system (CNS) with treatments generally restricted to immunosuppression to reduce attack rate and for symptom management. Glial cells may be useful targets for future CNS regenerative therapies to reverse disease. Areas covered: In this review, the authors cover currently available multiple sclerosis treatments and examine potential upcoming therapies targeting glial cells. The potential for new therapeutic approaches in the treatment of progressive multiple sclerosis is examined. Expert opinion: Microglia, astrocytes, and oligodendrocytes are each promising targets for the disease-altering treatment of multiple sclerosis. Though challenging, the opportunities presented have great potential for CNS regeneration and further investigation of glial cells in therapy is warranted. Patient-specific combinatorial therapy targeting the three glial cell types is expected to be the future of MS treatment.

AB - Introduction: Multiple sclerosis is a serious demyelinating disease of the central nervous system (CNS) with treatments generally restricted to immunosuppression to reduce attack rate and for symptom management. Glial cells may be useful targets for future CNS regenerative therapies to reverse disease. Areas covered: In this review, the authors cover currently available multiple sclerosis treatments and examine potential upcoming therapies targeting glial cells. The potential for new therapeutic approaches in the treatment of progressive multiple sclerosis is examined. Expert opinion: Microglia, astrocytes, and oligodendrocytes are each promising targets for the disease-altering treatment of multiple sclerosis. Though challenging, the opportunities presented have great potential for CNS regeneration and further investigation of glial cells in therapy is warranted. Patient-specific combinatorial therapy targeting the three glial cell types is expected to be the future of MS treatment.

KW - Astrocyte

KW - CNS

KW - glial cells

KW - microglia

KW - multiple sclerosis

KW - oligodendrocyte

KW - remyelination

UR - http://www.scopus.com/inward/record.url?scp=85067217075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067217075&partnerID=8YFLogxK

U2 - 10.1080/14737175.2019.1614443

DO - 10.1080/14737175.2019.1614443

M3 - Article

VL - 19

SP - 481

EP - 494

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 6

ER -